About: Dapagliflozin/saxagliptin/metformin

An Entity of Type: combination drug, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Dapagliflozin/saxagliptin/metformin, sold under the brand name Qternmet XR among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin, saxagliptin, and metformin. It is taken by mouth. The drug is marketed by AstraZeneca.

Property Value
dbo:abstract
  • Dapagliflozin/saxagliptin/metformin, sold under the brand name Qternmet XR among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin, saxagliptin, and metformin. It is taken by mouth. The drug is marketed by AstraZeneca. The most common side effects include infections of the nose and throat, hypoglycaemia (low blood sugar) when used with a sulphonylurea and effects on the gut such as nausea (feeling sick), vomiting, diarrhoea, abdominal (tummy) pain and loss of appetite. Dapagliflozin/saxagliptin/metformin was approved for medical use in the United States in May 2019, and in the European Union in November 2019. Its marketing authorisation was withdrawn in the European Union in August 2020, and its approval was withdrawn in the US in April 2021, in both cases at the request of AstraZeneca. (en)
dbo:alternativeName
  • Qternmet XR, Qtrilmet (en)
dbo:casNumber
  • 2447636-43-1
dbo:kegg
  • D11711
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 63133048 (xsd:integer)
dbo:wikiPageLength
  • 8428 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1064521550 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • A10 (en)
dbp:atcSuffix
  • BD25 (en)
dbp:casNumber
  • 2447636 (xsd:integer)
dbp:class
dbp:component
  • Metformin (en)
  • Dapagliflozin (en)
  • Saxagliptin (en)
dbp:dailymedid
  • Qternmet (en)
dbp:kegg
  • D11711 (en)
dbp:legalEu
  • Rx-only (en)
dbp:legalUs
  • Rx-only (en)
dbp:routesOfAdministration
dbp:tradename
  • Qternmet XR, Qtrilmet (en)
dbp:type
  • combo (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Dapagliflozin/saxagliptin/metformin, sold under the brand name Qternmet XR among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin, saxagliptin, and metformin. It is taken by mouth. The drug is marketed by AstraZeneca. (en)
rdfs:label
  • Dapagliflozin/saxagliptin/metformin (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License